Pfizer Inc. (NYSE:PFE) Holdings Decreased by Allen Mooney & Barnes Investment Advisors LLC

Allen Mooney & Barnes Investment Advisors LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 15.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,753 shares of the biopharmaceutical company’s stock after selling 5,137 shares during the quarter. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Pfizer were worth $828,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in PFE. Moneta Group Investment Advisors LLC grew its stake in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Norges Bank bought a new position in Pfizer during the 4th quarter worth $3,150,472,000. Charles Schwab Investment Management Inc. grew its stake in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley grew its stake in Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in Pfizer during the 1st quarter worth $311,238,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Barclays reduced their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. UBS Group reduced their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Truist Financial reduced their price target on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Trading Down 0.2 %

NYSE:PFE opened at $27.70 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1-year low of $25.61 and a 1-year high of $42.22. The firm has a market capitalization of $156.85 billion, a price-to-earnings ratio of 76.94, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The stock has a fifty day simple moving average of $27.44 and a 200 day simple moving average of $29.34.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the company posted $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.